Process for the preparation of basic antibiotic-inorganic acid addition salts and intermediate oxalates
AssigneeEisai Co., Ltd.
InventorsAkio Kayano, Hiroyuki Chiba, Taiju Nakamura, Shin Sakurai, Hiroyuki Ishizuka, Hiroyuki Saito, Yuuki Komatsu, Manabu Sasho, Nobuaki Sato, Shigeto Negi
Life of this patent
Estimating the term…
Abstract
A production process which comprises subjecting a basic antibiotic.oxalate (II) to salt-exchange with an alkali earth metal salt (III) of an inorganic acid: wherein the ring A means the basic antibiotic; R10 means a protected functional group used in organic synthesis; Ak—E means the alkali earth metal; and B means the inorganic acid, respectively.
Claims13
A process for producing a basic antibiotic.inorganic acid salt (I) wherein the basic antibiotic.inorganic acid salt (I) is selected from the group consisting of:
- (1) cefotiam hydrochloride;
- (2) cefmenoxime hydrochloride;
- (3) cefozopran hydrochloride;
- (4) cefpirome sulfate;
- (5) cefepime hydrochloride;
- (6) cefoselis sulfate;
- (7) cefotiam hexetil hydrochloride;
- (8) cefetamet pivoxil hydrochloride;
- (9) cefcapene pivoxil hydrochloride;
- (10) talampicillin hydrochloride;
- (11) bacampicillin hydrochloride;
- (12) lenampicillin hydrochloride;
- (13) pivmecillinam hydrochloride;
- and
- (14) (1R,5S,6S)-6-[(R)-1-hydroxyethyl]-1-methyl-2-{(2S,4S)-2-[(3R)-pyrrolidine-3-yl-(R)-hydroxy]methyl}pyrrolidine-4-ylthio]-1-carbapen-2-em-3-carboxylic acid.hydrochloride, said process comprising:
- subjecting a basic antibiotic.oxalate (II) to salt-exchange with an alkali earth metal salt (III) of an inorganic acid:
- wherein the ring A represents the basic antibiotic;
- R10 represents a protected functional group;
- Ak—E represents the alkali earth metal;
- and B represents the inorganic acid;
- and
- producing said basic antibiotic.inorganic acid salt (I).
A process for producing p-nitrobenzyl(1R,5S,6S)-6-[(R)-1-hydroxyethyl]-1-methyl-2-{(2S,4S)-2-[(3R)-pyrrolidine-3-yl-(R)-hydroxy]methyl}pyrrolidine-4-ylthio]-1-carbapen-2-em-3-carboxylate.oxalate (II-III), which comprises:
- reacting p-nitrobenzyl(1R,5S,6S)-6-[(R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylate-2-active compound (XIV) represented by the following formula:
- wherein PNB has the same meaning as described above;
- and L represents a leaving group, with (2S,4S)-2-{[(3R)-pyrrolidine-3-yl-(R)-hydroxy]methyl}-4-mercaptopyrrolidine.dihydrochloride (XV) represented by the following formula:
- then converting the resultant into an oxalate.
p-Nitrobenzyl(1R,5S,6S)-6-[(R)-1-hydroxyethyl]-1-methyl-2-{(2S,4S)-2-[(3R)-pyrrolidine-3-yl-(R)-hydroxy]methyl}pyrrolidine-4-ylthio]-1-carbapen-2-em-3-carboxylate.oxalate (II-III) represented by the following formula:
- wherein PNB represents p-nitrobenzyl group.
(1R,5S,6S)-6-[(R)-1-hydroxyethyl]-1-methyl-2-{(2S,4S)-2-[(3R)-pyrrolidine-3-yl-(R)-hydroxy]methyl}pyrrolidine-4-ylthio]-1-carbapen-2-em-3-carboxylate-oxalate (II-IX) represented by the following formula:
A process for producing (1R,5S,6S)-6-[(R)-1-hydroxyethyl]-1-methyl-2-{(2S,4S)-2-[(3R)-pyrrolidine-3-yl-(R)-hydroxy]methyl}pyrrolidine-4-ylthio]-1-carbapen-2-em-3-carboxylic acid.hydrochloride (VIII) represented by the following formula:
- said method comprising:
- subjecting a basic antibiotic protector-oxalate of p-nitrobenzyl(1R,5S,6S)-6-[(R)-1-hydroxyethyl]-1-methyl-2-{(2S,4S)-2-[(3R)-pyrrolidine-3-yl-(R)-hydroxy]methyl}pyrrolidine-4-ylthio]-1-carbapen-2-em-3-carboxylate.oxalate (VII) represented by the following formula:
- wherein PNB represents p-nitrobenzyl group, to deprotection reaction;
- then subjecting to salt-exchange with calcium chloride;
- then crystallizing the resultant after said salt-exchange by adding methanol and/or isopropanol;
- and
- to producing said basic (1R,5S,6S)-6-[(R)-1-hydroxyethyl]-1-methyl-2-{(2S,4S)-2-[(3R)-pyrrolidine-3-yl-(R)-hydroxy]methyl}pyrrolidine-4-ylthio]-1-carbapen-2-em-3-carboxylic acid.hydrochloride (VIII).
A process for producing a basic antibiotic.inorganic acid salt (I), said method comprising:
- subjecting a basic antibiotic.oxalate (II) to salt-exchange with an alkali earth metal salt (III) of an inorganic acid:
- wherein the ring A represents the basic antibiotic;
- R10 represents a protected functional group;
- Ak—E represents the alkali earth metal;
- and B represents the inorganic acid;
- and
- producing said basic antibiotic.inorganic acid salt (I);
- wherein said basic antibiotic.oxalate (II) is an oxalate (II-I) of a carbapenem compound, represented by the following formula:
- wherein the ring A means a 3- to 7-membered ring having at least one nitrogen atom;
- R1 represents hydrogen or methyl group;
- R2 and R5 are the same as or different from each other and each represents hydrogen or a hydroxyl-protecting group;
- R3 represents a carboxyl-protecting group;
- R4 represents hydrogen, a lower alkyl group or an amino-protecting group;
- and
- R6 represents (1) hydrogen, (2) an optionally protected hydroxyl group, carbamoyl, formimidoyl, acetoimidoyl or a lower alkyl group which may be substituted with a substituent represented by the formula:
- wherein R7 and R8 are the same as or different from each other and each represents hydrogen, a lower alkyl groups or an amino-protecting group, or (3) an amino-protecting group or an imino-protecting group;
- and
- m is 0 or 1.
An oxalate (II-I) of a carbapenem compound, represented by the following formula:
- wherein the ring A represents a 3- to 7-membered ring having at least one nitrogen atom, and the ring A is optionally substituted with a substituent other than R6;
- R1 represents hydrogen or methyl group;
- R2 and R5 are the same as or different from each other and each represents hydrogen or a hydroxyl-protecting group;
- R3 represents a carboxyl-protecting group;
- R4 represents hydrogen, a lower alkyl group or an amino-protecting group;
- R6 represents (1) hydrogen, (2) an optionally protected hydroxyl group, carbamoyl, formimidoyl, acetoimidoyl or a lower alkyl group which may be substituted with a substituent represented by the formula:
- wherein R7 and R8 are the same as or different from each other and each represents hydrogen, a lower alkyl groups or an amino-protecting group, or (3) an amino-protecting group or an imino-protecting group;
- and
- m is 0 or 1.
6-(1-Hydroxyethyl)-1-methyl-2-{[2-(pyrrolidine-3-yl)hydroxymethylpyrrolidine-4-yl]thio}-1-carbapen-2-em-3-carboxylic acid derivative.oxalate (II-II) represented by the following formula:
- wherein R3 represents a carboxyl-protecting group.
Dependencies are inferred from the claim text.